Andorra vs Türkiye: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Andorra
93.0%
in 2025
Türkiye
92.0%
in 2025
Andorra rank
53rd
Türkiye rank
56th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Andorra
- Türkiye
How they compare
Andorra currently reports 93.0% against 92.0% in Türkiye, a difference of 1.0%.
The two have swapped places 5 times across 18 shared years of data; in 2008 it was Türkiye ahead.
Andorra ranks 53rd and Türkiye ranks 56th of 194 countries.
Across the 3 decades both report, Andorra averaged higher in 1 and Türkiye in 2.
Head to head by decade
| Decade | Andorra | Türkiye | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 48.5% | 48.5% | Türkiye |
| 2010s | 56.5% | 96.4% | 39.9% | Türkiye |
| 2020s | 94.8% | 94.5% | 0.3% | Andorra |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Andorra or Türkiye?
- Andorra, at 93.0% against 92.0% in Türkiye as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Andorra and Türkiye?
- 1.0%, with Andorra ahead.
- How many years of comparable data are there for Andorra and Türkiye?
- 18 years are reported by both, from 2008 to 2025.
- How do Andorra and Türkiye rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Andorra ranks 53rd and Türkiye ranks 56th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.